Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 5
2015 11
2016 5
2017 6
2018 8
2019 11
2020 10
2021 17
2022 23
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Oclacitinib 10 years later: lessons learned and directions for the future.
Marsella R, Doerr K, Gonzales A, Rosenkrantz W, Schissler J, White A. Marsella R, et al. J Am Vet Med Assoc. 2023 Mar 25;261(S1):S36-S47. doi: 10.2460/javma.22.12.0570. Print 2023 Jun 1. J Am Vet Med Assoc. 2023. PMID: 36944222 Review.
Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in dogs. ...The purpose of this review is to present the current knowledge on the efficacy, speed of action, effects on the immune system, and
Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in
A Comprehensive Overview of Globally Approved JAK Inhibitors.
Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. Shawky AM, et al. Pharmaceutics. 2022 May 6;14(5):1001. doi: 10.3390/pharmaceutics14051001. Pharmaceutics. 2022. PMID: 35631587 Free PMC article. Review.
These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, tofacitinib, and upadacitinib. ...
These drugs are abrocitinib, baricitinib, delgocitinib, fedratinib, filgotinib, oclacitinib, pacritinib, peficitinib, ruxolitinib, to …
Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis.
De Caro Martins G, da Costa-Val AP, Coura FM, Diamantino GML, Nogueira MM, de Oliveira Melo-Junior OA, Giunchetti RC, da Silveira-Lemos D, Melo MM. De Caro Martins G, et al. Vet Dermatol. 2022 Apr;33(2):142-e40. doi: 10.1111/vde.13037. Epub 2021 Nov 7. Vet Dermatol. 2022. PMID: 34747068
However, the impact of chronic oclacitinib use on immunocompetence requires further investigation. OBJECTIVES: Herein, we examined the potential immunomodulatory effects of prolonged oclacitinib treatment in dogs. ANIMALS: Thirteen privately owned dogs with cAD, tre …
However, the impact of chronic oclacitinib use on immunocompetence requires further investigation. OBJECTIVES: Herein, we examined th …
A pharmacokinetic study of oclacitinib maleate in six cats.
Ferrer L, Carrasco I, Cristòfol C, Puigdemont A. Ferrer L, et al. Vet Dermatol. 2020 Apr;31(2):134-137. doi: 10.1111/vde.12819. Epub 2019 Nov 26. Vet Dermatol. 2020. PMID: 31769185
BACKGROUND: Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. ...OBJECTIVE: To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous admin …
BACKGROUND: Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic …
Use of oclacitinib as antipruritic drug during sarcoptic mange infestation treatment.
Cornegliani L, Guidi E, Vercelli A. Cornegliani L, et al. Vet Dermatol. 2020 Dec;31(6):505. doi: 10.1111/vde.12920. Vet Dermatol. 2020. PMID: 33226173
The aim of this retrospective study was to evaluate efficacy of oclacitinib in alleviating pruritus and inflammation in dogs affected by scabies. ...All dogs were treated at day (D)0 with systemic antiparasitic drugs (e.g. moxidectin, sarolaner, afoxolaner) in association …
The aim of this retrospective study was to evaluate efficacy of oclacitinib in alleviating pruritus and inflammation in dogs affected …
Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
Carrasco I, Ferrer L, Puigdemont A. Carrasco I, et al. J Feline Med Surg. 2022 Aug;24(8):787-793. doi: 10.1177/1098612X211048458. Epub 2021 Oct 6. J Feline Med Surg. 2022. PMID: 34612749
Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS). CONCLUSIONS AND RELEVANCE: Oclacitinib emerged as being safe and effective to control clinical signs of FASS. ...
Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS). CONCLUSIONS AND RELEVANCE: Oclacitinib
Treatment of the feline atopic syndrome - a systematic review.
Mueller RS, Nuttall T, Prost C, Schulz B, Bizikova P. Mueller RS, et al. Vet Dermatol. 2021 Feb;32(1):43-e8. doi: 10.1111/vde.12933. Vet Dermatol. 2021. PMID: 33470011 Review.
CONCLUSION AND CLINICAL RELEVANCE: In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and limited evidence for the efficacy of topical glucocorticoids, oclacitinib and allergen-specific immunotherapy in feline atopic skin …
CONCLUSION AND CLINICAL RELEVANCE: In this review, there was good evidence for the efficacy of systemic glucocorticoids and ciclosporin, and …
Oclacitinib (APOQUEL()) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.
Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Gonzales AJ, et al. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24. doi: 10.1111/jvp.12101. Epub 2014 Feb 5. J Vet Pharmacol Ther. 2014. PMID: 24495176 Free PMC article.
Oclacitinib was most potent at inhibiting JAK1 (IC50 = 10 nM). Oclacitinib also inhibited the function of JAK1-dependent cytokines involved in allergy and inflammation (IL-2, IL-4, IL-6, and IL-13) as well as pruritus (IL-31) at IC50 's ranging from 36 to 249 nM. ..
Oclacitinib was most potent at inhibiting JAK1 (IC50 = 10 nM). Oclacitinib also inhibited the function of JAK1-dependent cytok
109 results